Medullary thyroid carcinoma
Information
- Disease name
- Medullary thyroid carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04970134 | Active, not recruiting | Spanish Study for Molecular Characterization of Thyroid Carcinoma | June 14, 2021 | March 2024 | |
| NCT00880503 | Completed | Collection of Tissue Samples for Study of Multidrug Resistance | December 19, 2003 | February 8, 2018 | |
| NCT00514046 | Completed | Phase 1/Phase 2 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | July 20, 2007 | November 1, 2020 |
| NCT01424878 | Completed | Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients | July 5, 2010 | February 12, 2014 | |
| NCT01730638 | Completed | Phase 1/Phase 2 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma. | January 2013 | December 2016 |
| NCT02586350 | Completed | Phase 2/Phase 3 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | July 2015 | September 30, 2018 |
| NCT03246659 | Completed | Phase 1 | Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC | August 2016 | November 2018 |
| NCT06067594 | Completed | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | March 1, 2018 | June 1, 2022 | |
| NCT01511393 | Enrolling by invitation | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | January 2012 | December 2039 | |
| NCT06121271 | Not yet recruiting | Phase 2 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | December 18, 2023 | November 6, 2027 |
| NCT05534594 | Recruiting | N/A | Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer | August 19, 2022 | December 2024 |
| NCT04787328 | Recruiting | Phase 2 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | July 13, 2021 | March 2025 |
| NCT00923247 | Terminated | Phase 1/Phase 2 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | February 19, 2009 | December 9, 2016 |
| NCT03636945 | Unknown status | N/A | Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma | October 2018 | September 2021 |
| NCT01373736 | Unknown status | Phase 3 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | ||
| NCT01736878 | Withdrawn | Phase 2 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma | October 2012 | April 2013 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002865
- OrphaNumber from OrphaNet (Orphanet)
- 1332